Drugs / JMKX000189
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07601386 | May 2026 → Jun 2027 expected | chemotherapy-induced neuropathy | Shanghai Jeyou Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05967520 | Sep 2023 → May 2025 | systemic lupus erythematosus | Jemincare | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-22 | Jemincare | Regulatory 济民可信四项1类新药临床试验获批 jemincare.com ↗
JMKX000189注射液于近期获美国FDA批准，同意本品开展治疗急性缺血性脑卒中的临床试验。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-22 | Jemincare | 济民可信四项1类新药临床试验获批 jemincare.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMKX000189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07601386 ↗ |
| Route | Oral | “administered orally once a day” NCT05967520 ↗ |